GENcast: Explore, Learn, and Collaborate on Viral Safety in Biomanufacturing

Ask the average person on the street what they think of after hearing the phrase viral safety, and you will most likely be regaled with stories about scientists in hazmat suits saving Matt Damon from the next superbug destined to wipe out the human race. And, while cinematically I’m sure it would make for a great summer blockbuster, viral safety has a more subdued, but no less important role in many individual lives.

For biotherapeutic manufacturers, viral safety assurance is a critical aspect of upstream and downstream bioprocessing. As global regulatory agencies continue to be focused on patient safety, biopharma manufacturers need to be up to date with the latest technology and guidelines that help prevent, detect and remove viruses from raw materials. The scientists and engineers at the M Lab™ Collaboration Centers have experience with the latest tools, technologies, and regulations that are vital to virus-free bioproduction. In this podcast, we will hear from several members of the M Lab Collaboration Centers’ viral safety team who will discuss the common viral safety challenges that drug manufacturers encounter and the innovative solutions they have developed to address these issues.

This is the final installment in this the five-part podcast series tackling diverse issues such as next-generation bioprocessing, bioproduction training in emerging markets, cell and gene therapy manufacturing challenges, and regulatory challenges in Asia. Make sure you check out the other installments in this series!

Sladjana Tomic-Skrbic, PhD
Process Development Scientist Manager
MilliporeSigma